Decreased roundabout 1 expression promotes development of intrahepatic cholangiocarcinoma

Yohei Mano1, Shinichi Aishima, Takasuke Fukuhara

  • 1Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan; Department of Surgery and Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.

Human Pathology
|August 20, 2013
PubMed

Insights

Low expression of Roundabout 1 (Robo1) in intrahepatic cholangiocarcinoma (ICC) correlates with tumor growth and poor prognosis. This suggests Robo1 signaling is a potential therapeutic target for ICC development.

Area of Science:

  • Molecular Biology
  • Oncology
  • Cell Signaling

Background:

  • Roundabout 1 (Robo1) is an immunoglobulin family transmembrane receptor.
  • Slit2 is a known ligand for Robo1.
  • The role of Slit2/Robo1 signaling in intrahepatic cholangiocarcinoma (ICC) pathogenesis is not well understood.

Purpose of the Study:

  • To investigate the expression of Robo1 and Slit2 in ICC tissues.
  • To determine the clinicopathological implications of Robo1 and Slit2 expression in ICC.
  • To elucidate the functional role of Robo1 in ICC cell proliferation and migration.

Main Methods:

  • Immunohistochemical analysis of Robo1 and Slit2 expression in 132 ICC cases.
  • In vitro studies involving Robo1 knockdown (siRNA) and overexpression (vector transfection) in ICC cell lines (Huh28 and RBE).
  • Assessment of cell proliferation and migration under Slit2 stimulation.

Main Results:

  • Low Robo1 expression in ICC was associated with larger tumor size, higher Ki-67 index, and poor prognosis.
  • Low Slit2 expression was linked to perineural invasion and lymph node metastasis.
  • Robo1 suppression promoted ICC cell proliferation and migration, while overexpression suppressed these processes.

Conclusions:

  • Reduced Robo1 expression is linked to increased proliferation and migration in ICC cells.
  • Robo1 expression levels serve as an adverse prognostic factor in patients with ICC.
  • The Slit2/Robo1 pathway represents a potential therapeutic target for intrahepatic cholangiocarcinoma.